Wang Man, Yu Fei, Chen Xinzhe, Li Peifeng, Wang Kun
Institute for Translational Medicine, College of Medicine, Qingdao University, Qingdao 266021, China.
Institute for Translational Medicine, College of Medicine, Qingdao University, Qingdao 266021, China.
Mol Ther Nucleic Acids. 2020 Sep 4;21:13-27. doi: 10.1016/j.omtn.2020.05.011. Epub 2020 May 15.
Hepatocellular carcinoma (HCC) is one of the most lethal human malignancies. Chemotherapeutic agents, such as sorafenib and lenvatinib, can improve the outcomes of HCC patients. Nevertheless, chemoresistance has become a major hurdle in the effective treatment of HCC. Noncoding RNAs (ncRNAs), including mircoRNAs (miRNAs), long ncRNAs (lncRNAs), and circular RNAs (circRNAs), have been demonstrated to participate in the onset and progression of HCC. Moreover, multiple lines of evidence have indicated that ncRNAs also play a pivotal role in HCC drug resistance. ncRNAs can regulate drug efflux and metabolism, glucose metabolism, cellular death pathways, and malignant characteristics in HCC. A deeper understanding of the molecular mechanisms responsible for ncRNA-mediated drug resistance in HCC will provide new opportunities for improving the treatment of HCC. In this review, we summarize recent findings on the molecular mechanisms by which ncRNAs regulate HCC chemoresistance, as well as their potential clinical implications in overcoming HCC chemoresistance.
肝细胞癌(HCC)是最致命的人类恶性肿瘤之一。化疗药物,如索拉非尼和仑伐替尼,可以改善HCC患者的治疗效果。然而,化疗耐药已成为有效治疗HCC的主要障碍。非编码RNA(ncRNA),包括微小RNA(miRNA)、长链非编码RNA(lncRNA)和环状RNA(circRNA),已被证明参与了HCC的发生和发展。此外,多项证据表明,ncRNA在HCC耐药中也起着关键作用。ncRNA可以调节HCC中的药物外排和代谢、葡萄糖代谢、细胞死亡途径以及恶性特征。深入了解HCC中ncRNA介导的耐药分子机制将为改善HCC治疗提供新的机会。在本综述中,我们总结了ncRNA调节HCC化疗耐药的分子机制的最新发现,以及它们在克服HCC化疗耐药方面的潜在临床意义。